Jeffrey J. Olson
Experienced in Syringomyelia

Dr. Jeffrey J. Olson

Neurosurgery
Emory Clinic At 1365 Clifton Road
1365 Clifton Road Northeast, BldgB, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
44 Years of Experience
Experienced in Syringomyelia
Emory Clinic At 1365 Clifton Road
1365 Clifton Road Northeast, BldgB, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Olson is a Neurosurgery provider in Atlanta, Georgia. Dr. Olson has been practicing medicine for over 44 years and is rated as an Experienced provider by MediFind in the treatment of Syringomyelia. His top areas of expertise are Glioblastoma, Astrocytoma, Gliosarcoma, Awake Craniotomy, and Nerve Decompression.

His clinical research consists of co-authoring 234 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Minnesota Medical School Of Medicine, 1981
Residency
Univ of Iowa Hospitals & Clinics
Specialties
Neurosurgery
Licenses
Neurological Surgery in GA
Board Certifications
American Board Of Neurological Surgery, 1989
Fellowships
National Institute of Health, Clinic Center
Hospital Affiliations
Emory University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Emory Clinic at 1365 Clifton Road
1365 Clifton Road Northeast, BldgB, Atlanta, GA 30322

Additional Areas of Focus

Dr. Olson has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Radiation, Biological
Study Drugs: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Study Phase: Phase 2/Phase 3
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: INO-5401, INO-9012, Cemiplimab, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Enrollment Status: Completed
Publish Date: February 25, 2019
Intervention Type: Drug, Procedure
View 6 Less Clinical Trials

233 Total Publications

Label-Free, Real-Time, In Vivo Optical Biopsy with a Handheld Quantitative Phase Microscope.
Label-Free, Real-Time, In Vivo Optical Biopsy with a Handheld Quantitative Phase Microscope.
Journal: bioRxiv : the preprint server for biology
Published: September 26, 2025
Similar Doctors
Distinguished in Syringomyelia
Dr. Joshua Chern
Neurosurgery
Distinguished in Syringomyelia
Dr. Joshua Chern
Neurosurgery
5461 Meridian Mark Rd Ste 520, 
Atlanta, GA 
 (8.0 miles away)
404-785-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joshua Chern is a Neurosurgery provider in Atlanta, Georgia. Dr. Chern is rated as a Distinguished provider by MediFind in the treatment of Syringomyelia. His top areas of expertise are Chiari Malformation, Chiari Malformation Type 2, Chiari Malformation Type 1, Posterior Fossa Decompression, and Spinal Fusion.

Gerald (. Rodts
Advanced in Syringomyelia
Dr. Gerald (. Rodts
Neurosurgery
Advanced in Syringomyelia
Dr. Gerald (. Rodts
Neurosurgery

Emory University Hospital Midtown Campus

550 Peachtree Street Northeast, MedicalOfficeTower, 
Atlanta, GA 
 (3.6 miles away)
404-778-7000
Experience:
38+ years
Languages Spoken:
English, French, Spanish
See accepted insurances
Offers Telehealth

Gerald Rodts is a Neurosurgery provider in Atlanta, Georgia. Dr. Rodts has been practicing medicine for over 38 years and is rated as an Advanced provider by MediFind in the treatment of Syringomyelia. His top areas of expertise are Spinal Stenosis, Spondylolisthesis, Diffuse Idiopathic Skeletal Hyperostosis, Laminectomy, and Microdiscectomy.

Matthew Gary
Advanced in Syringomyelia
Dr. Matthew Gary
Neurosurgery
Advanced in Syringomyelia
Dr. Matthew Gary
Neurosurgery

Emory University Hospital Midtown Campus

550 Peachtree Street Northeast, MedicalOfficeTower, 
Atlanta, GA 
 (3.6 miles away)
404-778-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Gary is a Neurosurgery provider in Atlanta, Georgia. Dr. Gary is rated as an Advanced provider by MediFind in the treatment of Syringomyelia. His top areas of expertise are Cervical Myelopathy, Spinal Stenosis, Cervical Spondylosis, Laminectomy, and Microdiscectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Olson's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 11 Distinguished Conditions
View All 47 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile